Castle BiosciencesCSTL
CSTL
About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Employees: 710
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
844% more call options, than puts
Call options by funds: $8.7M | Put options by funds: $921K
169% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 16
52% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 48
33% more capital invested
Capital invested by funds: $554M [Q2] → $736M (+$182M) [Q3]
16% more funds holding
Funds holding: 158 [Q2] → 184 (+26) [Q3]
0.9% more ownership
Funds ownership: 92.19% [Q2] → 93.09% (+0.9%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
44%
upside
Avg. target
$40
62%
upside
High target
$44
76%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Stephens & Co. Mason Carrico 68% 1-year accuracy 13 / 19 met price target | 64%upside $41 | Overweight Reiterated | 2 Jan 2025 |
Scotiabank Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target | 76%upside $44 | Sector Outperform Maintained | 6 Nov 2024 |
Lake Street Thomas Flaten 9% 1-year accuracy 1 / 11 met price target | 60%upside $40 | Buy Maintained | 5 Nov 2024 |
Keybanc Paul Knight 38% 1-year accuracy 3 / 8 met price target | 44%upside $36 | Overweight Maintained | 5 Nov 2024 |
Baird Catherine Ramsey 83% 1-year accuracy 10 / 12 met price target | 56%upside $39 | Outperform Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 5 articles about CSTL published over the past 30 days
Neutral
Business Wire
3 days ago
Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of tests for skin cancer through poster presentations at the Maui Derm Hawaii meeting.
Neutral
Business Wire
1 week ago
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024. “Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the strength of our growth initiatives and the dedication of our team,” said Derek Maetzold, president and chief executiv.
Neutral
Business Wire
2 weeks ago
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Esophagus test.
Positive
Zacks Investment Research
4 weeks ago
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL.
Neutral
Business Wire
4 weeks ago
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis.
Neutral
Business Wire
1 month ago
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employees.
Positive
Zacks Investment Research
1 month ago
4 Solid Net Profit Margin Stocks to Boost Portfolio Returns
Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Business Wire
1 month ago
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences' DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Meta-analysis concludes DecisionDx-Melanoma provides improved risk stratification over staging alone to inform personalized management of melanoma.
Positive
Zacks Investment Research
1 month ago
Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside
These five small cap stocks have strong growth potential for 2025. These are: TALK, RYAM, CSTL, PBAM, RSSS.
Charts implemented using Lightweight Charts™